Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 22

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
840,358 $1 $(687,212)$153,149 Stock-based compensation expense— — 5,681 — — 5,681 Change in unrealized loss on investments, net of tax— — — (16)— (16)Net loss— — — — (51,890)(51,890)Balance as of March 31, 2025131,160,842 $2 $846,039 $(15)$(739,102)$106,924 Exercise of pre-funded warrants3,199,984 — — — — — Issuance of common stock under the employee stock purchase plan133,612 — 197 — — 197 Stock-based compensation expense— — 6,325 — — 6,325 Change in unrealized loss on investments, net of tax— — — 5 — 5 Net loss— — — — (52,591)(52,591)Balance as of June 30, 2025134,494,438 $2 $852,561 $(10)$(791,693)$60,860 Issuance of common stock from public offering, net of issuance costs of $5.8 million43,700,000 — 138,380 — — 138,380 Issuance of restricted stock units2,000,000 — — — — — Issuance of common stock upon exercise of stock options115,033 — 373 — — 373 Stock-based compensation expense— — 12,747 — — 12,747 Change in unrealized loss on investments, net of tax— — — 43 — 43 Net loss— — — — (50,582)(50,582)Balance as of September 30, 2025180,309,471 $2 $1,004,061 $33 $(842,275)$161,821 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Common StockAdditionalPaid-inCapitalAccumulated OtherComprehensiveLosses